Determinants for Aggressive End-of-Life Care for Oral Cancer Patients

A Population-Based Study in an Asian Country

Ting-Shou Chang, MD, Yu-Chieh Su, MD, and Ching-Chih Lee, MD, PhD

Abstract: Few studies have addressed the association between oral cancer and end-of-life (EOL) aggressive care using population data. We investigated the relationship between patient demographics, primary physician's specialty, and hospital characteristics of patients who died from oral cancer in Taiwan from 2009 to 2011 and the aggressiveness of their EOL care.

This nationwide population-based, retrospective cohort study identified 5386 patients who died from oral cancer identified from Taiwan's National Register of Deaths Database and collected their claims data from Taiwan's National Health Insurance Research Database. Accepted indicators of aggressiveness of EOL care were examined using a composite measure adapted from Earle et al. Scores ranged from 0 to 6; the higher the score, the more aggressive the EOL care. The impact of each variable on the aggressiveness of EOL care was examined by multivariate analysis using a random-intercept model.

The mean composite score for aggressiveness of EOL care was 2.68 ± 1.37. Oral cancer patients who were younger, had a higher level of comorbidity or metastasis, belonged to a lower-level individual socioeconomic status, were cared for by nononcologists, had longer postdiagnosis survival times, or resided in urban areas were more likely to receive aggressive care at EOL. Compared with previous studies, oral cancer patients near death in this nationwide study had a far higher utilization rate (>50%) of chemotherapy, emergency room services, and intensive care unit services.

Our findings indicate that oral cancer patients receive extensive aggressive medical care at EOL. Future research may be needed to examine the effect of the means (indicators) of aggressive treatment on survival, quality of life, and medical costs, especially since current research suggests such care may adversely affect quality of life and important preparation of death in these patients.

INTRODUCTION

Oral cancer is one of the 10 most common cancers in the world. Its incidence has been rising not only in Asian countries such as Taiwan where betel nut consumption is high but also now in Western countries. Oral cancer makes up for 70% of all head and neck cancers in Taiwanese males, and has been ranked fourth in incidence and mortality in that population since 1995. Treatment of this disease amounted to US$1195 million in Taiwan in 2004. These expenditures are expected to increase dramatically in this decade, making oral cancer treatment a serious socioeconomic problem for a country that provides national health insurance (NHI) and an important public health issue.

An initial diagnosis of advanced-stage oral cancer carries with it a 35% chance of being cured. As the disease progresses, there is a concomitant increase in physical distresses and functional challenges. Although there are many different treatment options available to help relieve uncontrolled suffering of oral cancer at end-of-life (EOL), there is a paucity of information regarding the prognosis of this disease, treatment modalities, and the possible complications of medical care. This makes proper EOL treatment decision making very difficult.

Previous studies from around the world have reported increasing aggressiveness in treatment for cancer near EOL, including increases in chemotherapy, hospital stay, intensive care unit (ICU) admission, emergency room (ER) visits, and deaths during acute care hospitalizations. In many instances, not only these treatments do not cure disease but they are also performed at high cost and compromise the quality of life of the patient close to death. These studies, however, focus on the impact of aggressive EOL treatment for all cancers, not on oral cancer, which is now on the increase outside of Asia.

This study uses the nationwide claims data from Taiwan's National Health Insurance Research Database (NHIRD) for patients who died from oral cancer between 2009 and 2011 to investigate the determinants of aggressive medical care for patients with oral cancer near death. This database provides basic demographic data as well as socioeconomic status (SES),
METHODS

Ethics Statement
This study was approved by the Institutional Review Board of Buddhist Dalin Tzu Chi General Hospital, Taiwan. Review board requirements for written informed consent were waived because all personal identifying information was removed from the data set prior to analysis.

Database
We first accessed the National Register of Deaths Database to identify 5386 patients who died from oral cancer from 2009 to 2011. We then collected individual patient-level data for this study from Taiwan’s NHIRD for the years 2009 to 2011. This data set is organized and managed by Taiwan’s National Health Research Institutes but collected by Taiwan’s NH program, which has been in place in Taiwan since 1995. The program covers approximately 99% of the residents in Taiwan and has contracts with 97% of the medical providers there.12 To verify accuracy of diagnosis, Taiwan’s Bureau of National Health Insurance randomly reviews the charts of 1 per 100 ambulatory and 1 per 20 inpatient claims and interviews patients.13,14 Taiwan’s NH program is a single-payer system with the government as sole insurer and provides universal insurance coverage for comprehensive array of medical services for all of Taiwan’s residents. Patients have free access to any medical care provider they choose as long as that provider has a contract with the Bureau of National Health Insurance.

Measurement
Aggressiveness of EOL Care
This study adopted the 6 indicators of aggressiveness of EOL care from Earle et al.7,15 These 6 indicators were use of chemotherapy, more than 1 ER visit, more than 1 hospital admission, more than 14 days of hospitalization, an ICU admission, and death in acute care hospital, all within the last month of life. Data for all of these indicators could be collected from Taiwan’s NHIRD, which maintains records for all inpatient or outpatient claims for the last month of life. Regardless of whether a patient was enrolled in hospice home care or inpatient hospice services in the last month of life, hospitalization was not counted as aggressive care. Each person who died from oral cancer received a score of 1 point per indicator. With a total of 6 indicators, the composite score for each person ranged from 0 to 6, with higher scores indicating more aggressive EOL care.

Patient Demographics
Patient characteristics included age, gender, postdiagnosis survival time, geographic location, urbanization level of residence, individual SES, cancer metastatic status, and severity of comorbidity. The recoding and definition of SES and urbanization of residence was mentioned in our previous study.16 Severity of comorbidity was based on the modified Charlson Comorbidity Index Score recorded on the claims database for the last 6 months of each patient’s life. The Charlson Comorbidity Index Score is a widely accepted scale used for risk adjustment in administrative claims data sets.17 Oral cancer metastatic status was identified by International Classification of Diseases, Ninth Revision, codes 196.xx to 199.xx.

Primary Physician’s Specialty and the Characteristics of the Primary Hospital
The primary physician’s specialty was identified from NHI claims and was dichotomized into oncologist versus other. The hospitals were categorized by hospital level (medical center, regional, or district hospital), caseload volume (high, medium, or low), and hospital spending intensity (high, medium, or low). The hospital caseload volume was sorted by their total patient volume using unique hospital identifiers reported in a previous study.18 The hospital spending index used in this study was based on the hospital EOL expenditure index, defined as the mean spending of hospitalization of patients in their last 6 months of life, modified from previous literature.19

Statistical Analysis
All statistical operations were performed using SPSS (version 15; SPSS Inc, Chicago, IL). The impact of each explanatory variable on the aggressiveness of EOL care tool was examined by multivariate analysis using a random-intercept model, which accounts for patient clustering within hospitals and the continuous nature of the composite score for EOL care. A hospital-level random effect can account for possible correlations between EOL care within a hospital’s panel because of hospital policies, facilities, or physician compensation mechanisms that are unique to a particular hospital. A 2-tailed value of P < 0.05 was considered significant.

RESULTS
A total of 5386 patients who died from oral cancer from 2009 to 2011 were identified in the National Register of Deaths Database. As can be seen in Table 1, which shows a summary of patient characteristics, mean age at death was 57 ± 13 years. The majority (72.5%) of patients who died from oral cancer were between 35 and 64 years old. Most (64%) also had metastatic disease. Among the decedents with oral cancer, almost 30% died within 6 months after diagnosis. In the last month of life, 15.4% of these patients were treated by oncologists.

As can be seen in Figure 1, which shows a line graph depicting distribution of aggressive EOL care indicators over 3 years, the mean composite score for aggressiveness of EOL care was 2.68 ± 1.37 with most oral cancer patients (96.1%) having at least 1 indicator of aggressive EOL care (Table 2). In the majority of these patients, there was an increase in frequency of ER visits and ICU admissions in the last month of life in 2010 and 2011 compared with that in 2009. Besides, only 644 (12%) patients enrolled in hospice services in the last month of life.

Compared with the composite aggressive EOL care scores of 2009, those of 2010 and 2011 were not significantly higher (P = 0.150 and 0.626, respectively), after controlling for other variables (Table 3). EOL care was found to be less aggressive for oral cancer patients who belonged to a high SES, who were older than 85 years, who resided in rural areas, who were primarily cared for by oncologists, and who had postdiagnosis survival times shorter than 6 months. It was found to be significantly more aggressive for those with higher levels of comorbidity and disease with metastasis (both P < 0.001). Aggressiveness of EOL care was not found to be influenced by gender, geographic region, or hospital characteristics, which included hospital level, hospital spending intensity, and caseload volume.
TABLE 1. Baseline Characteristics

| Parameter                                | Total           | Year   |       | Year   |       | Year   |       |
|------------------------------------------|-----------------|--------|-------|--------|-------|--------|-------|
|                                          | No.  | %    |       | No.  | %    |       | No.  | %    |       |
| Total                                    | 5386 | 100  |       | 1369 | 25.4 |       | 1808 | 33.6 |       | 2209 | 41.0 |
| Socioeconomic status                     |      |      |       |      |      |       |      |      |       |      |      |
| High                                     | 1418 | 26.3 |       | 355  | 25.9 |       | 448  | 24.8 |       | 615  | 27.8 |
| Medium                                   | 2244 | 41.7 |       | 551  | 40.2 |       | 761  | 42.1 |       | 932  | 42.2 |
| Low                                      | 1724 | 32.0 |       | 463  | 33.8 |       | 599  | 33.1 |       | 662  | 30.0 |
| Hospital spending index                  |      |      |       |      |      |       |      |      |       |      |      |
| High                                     | 1318 | 24.5 |       | 345  | 25.2 |       | 449  | 24.8 |       | 524  | 23.7 |
| Medium                                   | 3390 | 62.9 |       | 853  | 62.3 |       | 1118 | 61.8 |       | 1419 | 64.2 |
| Low                                      | 678  | 12.6 |       | 171  | 12.5 |       | 241  | 13.2 |       | 266  | 12.1 |
| Gender                                   |      |      |       |      |      |       |      |      |       |      |      |
| Male                                     | 5033 | 93.4 |       | 1281 | 93.6 |       | 1670 | 92.4 |       | 2082 | 94.3 |
| Female                                   | 353  | 6.6  |       | 88   | 6.4  |       | 138  | 7.6  |       | 127  | 5.7  |
| Mean age, years (±SD)                    | 57 ±13|      |       | 57 ±13|      |       | 57 ±13|      |       | 56 ±13|      |
| Age group, years                         |      |      |       |      |      |       |      |      |       |      |      |
| 18–34                                    | 99   | 1.8  |       | 36   | 2.6  |       | 32   | 1.8  |       | 31   | 1.4  |
| 35–44                                    | 882  | 16.4 |       | 238  | 17.4 |       | 295  | 16.3 |       | 349  | 15.8 |
| 45–54                                    | 1753 | 32.5 |       | 469  | 34.3 |       | 574  | 31.7 |       | 710  | 32.1 |
| 55–64                                    | 1271 | 23.6 |       | 280  | 20.5 |       | 444  | 24.6 |       | 547  | 24.8 |
| 65–74                                    | 784  | 14.6 |       | 195  | 14.2 |       | 263  | 14.5 |       | 326  | 14.8 |
| 75–84                                    | 459  | 8.5  |       | 113  | 8.3  |       | 148  | 8.2  |       | 198  | 9.0  |
| ≥85                                      | 138  | 2.6  |       | 38   | 2.8  |       | 52   | 2.9  |       | 48   | 2.2  |
| CCIS                                     |      |      |       |      |      |       |      |      |       |      |      |
| 0 or 1                                   | 1907 | 35.4 |       | 479  | 35.0 |       | 665  | 36.8 |       | 763  | 34.5 |
| 2                                        | 1038 | 19.3 |       | 283  | 20.7 |       | 333  | 18.4 |       | 422  | 19.1 |
| 3                                        | 398  | 7.4  |       | 102  | 7.5  |       | 135  | 7.5  |       | 161  | 7.3  |
| 4                                        | 2043 | 37.9 |       | 505  | 36.9 |       | 675  | 37.3 |       | 863  | 39.1 |
| Cancer group                             |      |      |       |      |      |       |      |      |       |      |      |
| Without metastasis                       | 1941 | 36.0 |       | 499  | 36.4 |       | 662  | 36.6 |       | 780  | 35.3 |
| With metastasis                          | 3445 | 64.0 |       | 870  | 63.6 |       | 1146 | 63.4 |       | 1429 | 64.7 |
| Postdiagnosis survival, mo               |      |      |       |      |      |       |      |      |       |      |      |
| ≤6                                       | 1499 | 27.8 |       | 447  | 32.7 |       | 504  | 27.9 |       | 548  | 24.8 |
| 7–12                                     | 1683 | 31.2 |       | 567  | 41.4 |       | 544  | 30.1 |       | 572  | 25.9 |
| 13–24                                    | 1650 | 30.6 |       | 355  | 25.9 |       | 602  | 33.3 |       | 693  | 31.4 |
| >25                                      | 554  | 10.3 |       | 0    | 0.0  |       | 158  | 8.7  |       | 396  | 17.9 |
| Primary physician’s specialty             |      |      |       |      |      |       |      |      |       |      |      |
| Oncologist                               | 831  | 15.4 |       | 213  | 15.6 |       | 284  | 15.7 |       | 334  | 15.1 |
| Other                                    | 4555 | 84.6 |       | 1156 | 84.4 |       | 1524 | 84.3 |       | 1875 | 84.9 |
| Hospital characteristics                 |      |      |       |      |      |       |      |      |       |      |      |
| Medical center                           | 3828 | 71.1 |       | 975  | 71.2 |       | 1291 | 71.4 |       | 1562 | 70.7 |
| Regional                                 | 1461 | 27.1 |       | 364  | 26.6 |       | 486  | 26.9 |       | 611  | 27.7 |
| District                                 | 97   | 1.8  |       | 30   | 2.2  |       | 31   | 1.7  |       | 36   | 1.6  |
| Caseload group                           |      |      |       |      |      |       |      |      |       |      |      |
| High                                     | 1255 | 23.3 |       | 278  | 20.3 |       | 423  | 23.4 |       | 554  | 25.1 |
| Medium                                   | 2132 | 39.6 |       | 566  | 41.3 |       | 719  | 39.8 |       | 847  | 38.3 |
| Low                                      | 1999 | 37.1 |       | 525  | 38.3 |       | 666  | 36.8 |       | 808  | 36.6 |
| Urbanization                             |      |      |       |      |      |       |      |      |       |      |      |
| Urban                                    | 1244 | 23.1 |       | 312  | 22.8 |       | 406  | 22.5 |       | 526  | 23.8 |
| Suburban                                 | 2361 | 43.8 |       | 614  | 44.9 |       | 787  | 43.5 |       | 960  | 43.5 |
| Rural                                    | 1781 | 33.1 |       | 443  | 32.4 |       | 615  | 34.0 |       | 723  | 32.7 |
| Geographic Region                        |      |      |       |      |      |       |      |      |       |      |      |
| Northern                                 | 2351 | 43.7 |       | 609  | 44.5 |       | 767  | 42.5 |       | 975  | 44.2 |
| Central                                  | 1042 | 19.4 |       | 274  | 20.0 |       | 356  | 19.7 |       | 412  | 18.7 |
| Southern                                 | 1698 | 31.5 |       | 419  | 30.6 |       | 571  | 31.6 |       | 708  | 32.1 |
| Eastern                                  | 291  | 5.4  |       | 67   | 4.9  |       | 111  | 6.1  |       | 113  | 5.1  |

CCIS = Charlson Comorbidity Index Score, SD = standard deviation.
In this study tapping Taiwan’s NHIRD claims records for patients who died from oral cancer between 2009 and 2011, it was found that 96.1% of those patients who died from this disease between 2009 and 2011 had at least 1 of the 6 indicators of aggressive care (forms of aggressive treatment) near the EOL used by Earle et al.,7,15 and that composite aggressive EOL care scores for 2010 and 2011 were not significantly higher than those found in 2009 (P = 0.150 and 0.626, respectively). There was a high utilization rate in chemotherapy, ER visits, and ICU admissions in the last month of life in more than 50% of these oral cancer patients.

The finding of tendency toward aggressiveness of care at EOL is consistent with those of earlier studies investigating aggressive EOL care and cancer death, although none studied oral cancer specifically.7–10 Those studies reported this trend to be increasing over time, but not seen in our result. Similar to previous reports,7–10,20,21 we found that patients who were elderly (≥85 years), who had lower level of comorbidity indices, who had no distant metastasis, or who were living in the rural area were less likely to receive aggressive EOL treatment. Our findings differ from previous findings first with regard to the impact of variables on aggressiveness of EOL care in our study population. Earle et al.,7,8 Tang et al.,9 Ho et al.,10 Saito et al.,20 and Warren et al.22 found that cancer patients who were male gender, who were primarily cared for by oncologists, who had higher-level individual SES, who had shorter post-diagnosis survival time, or who were treated in teaching hospitals were more likely to have 1 or more indicators of aggressive EOL care (eg, chemotherapy, ICU utilization, ER visits). Residence region was also a significant independent predictor of intensive EOL care in those studies. However, in our study of oral cancer patients, aggressiveness of EOL care was not influenced by sex, hospital teaching level, and residence area, and patients who had higher-level individual SES, who had shorter postdiagnosis survival times (<6 months), or who were treated by oncologists had lower composite aggressive EOL care scores. The reason may be due to poor prognosis of advanced-stage oral cancer that has not shown any significant improvement over the past few decades.23 Diseases have generally been treated much less aggressively if they were considered highly fatal.24 Previous studies did not investigate the relation between hospital spending and hospital caseload volume. We did, but found no significant difference with regard to the influence of these variables and aggressiveness of EOL care. Tang et al., studying a cohort of patients who died from cancer in Taiwan from 2001 to 2006, found that from 10% to 20% of cancer patients near death received chemotherapy, were admitted to ICUs, or had emergency department visits. However, we found that more than 50% of oral cancer patients near death were admitted to ICUs and had emergency department visits and almost 70% received chemotherapy in the last month

![FIGURE 1. Trends for the 6 indicators of aggressive EOL care for Taiwanese patients who died from oral cancer from 2009 to 2011. EOL = end-of-life, ER = emergency room, ICU = intensive care unit.](image-url)

## DISCUSSION

In this study tapping Taiwan’s NHIRD claims records for patients who died from oral cancer between 2009 and 2011, it was found that 96.1% of those patients who died from this disease between 2009 and 2011 had at least 1 of the 6 indicators of aggressive care (forms of aggressive treatment) near the EOL used by Earle et al.,7,15 and that composite aggressive EOL care scores for 2010 and 2011 were not significantly higher than those found in 2009 (P = 0.150 and 0.626, respectively). There was a high utilization rate in chemotherapy, ER visits, and ICU admissions in the last month of life in more than 50% of these oral cancer patients.

The finding of tendency toward aggressiveness of care at EOL is consistent with those of earlier studies investigating aggressive EOL care and cancer death, although none studied oral cancer specifically.7–10 Those studies reported this trend to be increasing over time, but not seen in our result. Similar to previous reports,7–10,20,21 we found that patients who were elderly (≥85 years), who had lower level of comorbidity indices, who had no distant metastasis, or who were living in the rural area were less likely to receive aggressive EOL treatment. Our findings differ from previous findings first with regard to the impact of variables on aggressiveness of EOL care in our study population. Earle et al.,7,8 Tang et al.,9 Ho et al.,10 Saito et al.,20 and Warren et al.22 found that cancer patients who were male gender, who were primarily cared for by oncologists, who had higher-level individual SES, who had shorter post-diagnosis survival time, or who were treated in teaching hospitals were more likely to have 1 or more indicators of aggressive EOL care (eg, chemotherapy, ICU utilization, ER visits). Residence region was also a significant independent predictor of intensive EOL care in those studies. However, in our study of oral cancer patients, aggressiveness of EOL care was not influenced by sex, hospital teaching level, and residence area, and patients who had higher-level individual SES, who had shorter post-diagnosis survival times (<6 months), or who were treated by oncologists had lower composite aggressive EOL care scores. The reason may be due to poor prognosis of advanced-stage oral cancer that has not shown any significant improvement over the past few decades.23 Diseases have generally been treated much less aggressively if they were considered highly fatal.24 Previous studies did not investigate the relation between hospital spending and hospital caseload volume. We did, but found no significant difference with regard to the influence of these variables and aggressiveness of EOL care. Tang et al., studying a cohort of patients who died from cancer in Taiwan from 2001 to 2006, found that from 10% to 20% of cancer patients near death received chemotherapy, were admitted to ICUs, or had emergency department visits. However, we found that more than 50% of oral cancer patients near death were admitted to ICUs and had emergency department visits and almost 70% received chemotherapy in the last month

## TABLE 2. Trends in Aggressive End-of-Life Care for Taiwanese Patients Who Died From Oral Cancer From 2009 to 2011

| Composite Score | 2009 | 2010 | 2011 |
|-----------------|------|------|------|
| %               |      |      |      |
| 0               | 212  | 54   | 66   |
| 1               | 878  | 250  | 274  |
| 2               | 1450 | 357  | 500  |
| 3               | 1374 | 336  | 458  |
| 4               | 934  | 226  | 327  |
| 5               | 415  | 116  | 142  |
| 6               | 123  | 30   | 41   |
| Average         | 2.68 | 2.66 | 2.72 |
| SD              | 1.37 | 1.39 | 1.35 |

SD = standard deviation.
Composite score measured aggressiveness of end-of-life care (scores range from 0 to 6).
| Parameter                               | Estimate (95% CI) | P Value  |
|-----------------------------------------|-------------------|----------|
| Intercept                               | 2.441 (2.084–2.798) | <0.001   |
| Socioeconomic status                    |                   |          |
| Low                                     | Reference         |          |
| Medium                                  | −0.090 (−0.176 to −0.004) | 0.039    |
| High                                    | −0.121 (−0.216 to −0.026) | 0.012    |
| Hospital spending index                 |                   |          |
| Low                                     | Reference         |          |
| Medium                                  | −0.213 (−0.367 to −0.059) | 0.007    |
| High                                    | 0.008 (−0.232 to 0.249) | 0.944    |
| Gender                                  |                   |          |
| Male                                    | Reference         |          |
| Female                                  | 0.075 (−0.073 to 0.224) | 0.319    |
| Age group, years                        |                   |          |
| <35                                     | Reference         |          |
| 35–44                                   | −0.108 (−0.384 to 0.167) | 0.442    |
| 45–54                                   | −0.086 (−0.356 to 0.182) | 0.528    |
| 55–64                                   | −0.078 (−0.352 to 0.194) | 0.571    |
| 65–74                                   | −0.225 (−0.505 to 0.055) | 0.116    |
| 75–84                                   | −0.363 (−0.655 to −0.071) | 0.015    |
| ≥85                                     | −0.495 (−0.844 to −0.146) | 0.005    |
| Charlson Comorbidity Index Score        |                   |          |
| 0 or 1                                  | Reference         |          |
| 2                                       | 0.432 (0.331–0.534) | <0.001   |
| 3                                       | 0.630 (0.485–0.775) | <0.001   |
| ≥4                                      | 0.464 (0.378–0.550) | <0.001   |
| Cancer group                            |                   |          |
| Without metastasis                      | Reference         |          |
| With metastasis                         | 0.203 (0.122–0.285) | <0.001   |
| Postdiagnosis survival, mo              |                   |          |
| 0–6                                     | Reference         |          |
| 6.01–12                                 | 0.168 (0.074–0.262) | <0.001   |
| 12.01–24                                | 0.116 (0.020–0.213) | 0.018    |
| >24                                     | 0.074 (−0.060 to 0.208) | 0.280    |
| Primary physician’s specialty            |                   |          |
| Other                                   | Reference         |          |
| Oncologist                              | −0.108 (−0.212 to −0.005) | 0.039    |
| Hospital characteristics                |                   |          |
| Medical center                          | Reference         |          |
| Regional                                | −0.094 (−0.248 to 0.058) | 0.216    |
| District                                | −0.086 (−0.411 to 0.237) | 0.599    |
| Caseload group                          |                   |          |
| High                                    | Reference         |          |
| Medium                                  | 0.193 (0.013–0.374) | 0.037    |
| Low                                     | 0.172 (−0.035 to 0.379) | 0.098    |
| Urbanization                            |                   |          |
| Urban                                   | Reference         |          |
| Suburban                                | −0.081 (−0.181 to 0.033) | 0.107    |
| Rural                                   | −0.146 (−0.276 to −0.024) | 0.014    |
| Geographic region                       |                   |          |
| Northern                                | Reference         |          |
| Central                                 | 0.136 (0.014–0.259) | 0.029    |
| Southern                                | 0.020 (−0.085 to 0.125) | 0.704    |
| Eastern                                 | 0.041 (−0.152 to 0.236) | 0.671    |
| Year                                    |                   |          |
| 2009                                    | Reference         |          |
| 2010                                    | 0.069 (−0.025 to 0.163) | 0.150    |
| 2011                                    | 0.023 (−0.069 to 0.116) | 0.626    |

CI = confidence interval.
of life. Our results suggest that physicians may have more aggressive attitude toward EOL treatment and provide more intensive treatment for oral cancer patients than for other cancer patients.

More than half of the oral cancer patients we studied had distant metastasis near death. Platinum-based chemotherapy in combination with cetuximab and taxane has been found to improve survival of head and neck cancer patients with distant metastasis.\textsuperscript{25–28} Therefore, it is not surprising that the oral cancer patients in our study had a higher rate of chemotherapy (>70%), although current salvage chemotherapy regimens may prolong life by a matter of months only and have response rates below 50%. Furthermore, platinum- or taxane-based chemotherapy was associated with significant comorbidity, including pancytopenia, nausea, vomiting, stomatitis, and renal toxicity.\textsuperscript{29} Oral surgeons may fear that they have not done enough in terms of surgery, chemotherapy, or radiotherapy, and may not pay as much attention to the possibility that they have done too much and adversely affected patients’ quality of life. Although symptoms related to oral cancer progression may require acute care utilization, the adverse effects of chemotherapy would result in increased numbers of ER visits, ICU admissions, and cases of unexpected toxic complications, which obviously affect quality of life and interfere with preparation for death.\textsuperscript{30}

Physicians tend to overestimate survival time for terminal cancer patients.\textsuperscript{31} They may also feel more comfortable suggesting alternate aggressive treatment goals rather than bringing up the topic of impending death, breaking bad news, and suggesting palliative care.\textsuperscript{9} Shifting to third- or fourth-line chemotherapy may be an easier topic to discuss than hospice care. Avoiding the topic or withholding detailed prognostic information can lead to patient mistrust of the health care system and medical profession, inappropriate use of life-sustaining medical treatments, increased medical complications, and long hospital stays.\textsuperscript{32} It seems as though physicians give the least honest figures to those with the worst prognoses, often creating unrealistic expectations regarding the potential success of aggressive treatment and interfering with their patients’ rights to autonomy and self-determination.\textsuperscript{33} A positive association has been found between early EOL discussions and decision to accept less aggressive care.\textsuperscript{34}

However, it is not all in the hands of the physicians, since even after the most frank communications regarding impending death, the patients, themselves, may hold unrealistic expectations and decide to continue chemotherapy.\textsuperscript{9} They may feel that doing something is better than doing nothing. Patients may also associate “palliative care” or “hospice care” with abandonment, an unpleasant emotion that many would prefer to avoid. Avoidance of this emotion can be achieved by distracting themselves with further treatments. Chen et al proposed exploring the subtypes of aggressive EOL care and the potential care quality problems could be better understood in each subtype.\textsuperscript{35} They classified patients who died from cancer into 3 subgroups based on the usage of aggressive EOL care, such as “not aggressive,” “intent to sustain life,” and “symptom crisis” group. Thirty-three percent patients who died from cancer were in the “intent to sustain life” subgroup, which was less likely to have metastatic disease and to receive hospice care in the EOL, but more likely to be cared for by nonmedical oncologists, to die within 2 months after diagnosis, and to die in hospital. Besides, the authors also found that the proportions of chemotherapy were similar among 3 subgroups. Chemotherapy for the terminally ill cancer patients was regarded as curative treatment rather than palliative treatment.

### Policy Implications

Taiwan’s health system is closely intertwined with its NHI program, which covers the health care of almost all of its residents. This universal health insurance program is indeed very costly and takes up much of the nation’s resources. Therefore, the problem of unnecessary or unrealistic aggressive treatment is also relevant. Increased aggressiveness translates into great economic burden.\textsuperscript{36,37} In our study, only 12% of oral cancer patients enrolled in hospice services in the last month of life. The more time spent on aggressive EOL care, the less time spent on hospice care. The shorter the time spent in hospice care, the less opportunity for realizing EOL care goals of life closure, comfortable dying, and effective grieving.\textsuperscript{38} Hospices provide comprehensive, high-quality care that eases oral cancer patients’ symptoms and prepares individuals and families for death. In a study of lung cancer patients with metastatic disease, Temel et al suggest that early palliative care can lead to significant improvements in quality of life, mood, and as much as 2 extra months of survival.\textsuperscript{39} Therefore, clinical and health policies might reduce focus on aggressive care when it will not benefit patients in favor of a more humanistic focus on patient comfort as well as more economic hospice care.

In fact, many terminally ill patients prefer home care, because they can be surrounded by their loved ones and minimize costs.\textsuperscript{40} There are, however, substantial disparities in access to hospice services.\textsuperscript{41} Tang et al have reported that less than one-third of patients who die from cancer receive hospice care at home in Taiwan.\textsuperscript{42} Therefore, it might be wise for the relevant authorities to encourage equanimity in availability of hospice care and provide more support for the training of hospice care providers.

### Limitations of the Study

This study has several limitations. One limitation is that the diagnosis of cancer and any comorbidity was completely dependent on International Classification of Diseases codes. There might have been some misclassification, although Taiwan’s Bureau of National Health Insurance randomly reviews the chart and interviews patients in order to verify diagnostic accuracy.\textsuperscript{13,14} Another limitation was that we could not use the claims database to evaluate satisfaction and quality of life in oral cancer patients. Still another limitation is the lack of detailed information about hospitalizations for diagnostic workup and chemotherapy for reducing symptoms among oral cancer patients in the last month of life. It would be overestimated if those hospitalizations and chemotherapy were considered as aggressive treatment at the EOL. However, given the robustness of the evidence and statistical analysis in this study, these limitations are unlikely to compromise our results.

### CONCLUSION

In summary, this study found that oral cancer patients who were younger in age, who had more comorbidity or metastasis, who belonged to a lower-level individual SES, who were primarily cared for by nononcologists, who had longer post-diagnosis survival times, or who resided in urban areas were more likely to receive more aggressive care at EOL. Oral cancer patients near death were also observed to have a far higher utilization rate of chemotherapy, ER services, and ICU services than other cancer patients near death. Future research may be needed to examine the effect of these 3 indicators on survival, quality of life, and medical costs.
REFERENCES

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.

2. Mignogna MD, Fedele S, Russo LL. The World Cancer Report and the burden of oral cancer. Eur J Cancer Prev. 2004;13:139–142.

3. Yang YH, Chen CH, Chang JS, et al. Incidence rates of oral cancer and oral pre-cancerous lesions in a 6-year follow-up study of a Taiwanese aboriginal community. J Oral Pathol Med. 2005;34:596–601.

4. Tobias JS. Cancer of the head and neck. BMJ. 1994;308:961–966.

5. Matsuyama R, Reddy S, Smith TJ. Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol. 2006;24:3490–3496.

6. Harrington SE, Smith TJ. The role of chemotherapy at the end of life: “when is enough, enough?” JAMA. 2008;299:2667–2678.

7. Earle CC, Neville BA, Landrum MB, et al. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol. 2004;22:315–321.

8. Earle CC, Landrum MB, Souza JM, et al. Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol. 2006;24:3860–3866.

9. Tang ST, Wu SC, Hung YN, et al. Determinants of aggressive end-of-life care for Taiwanese cancer decedents, 2001 to 2006. J Clin Oncol. 2009;27:4613–4618.

10. Ho TH, Barbera L, Sasaki R, et al. Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol. 2011;29:1587–1591.

11. Zilberberg MD, Shorr AF. Economics at the end of life: hospital and ICU perspectives. Semin Respir Crit Care Med. 2012;33:362–369.

12. NHI. NHI profile (updated May 2012). Http://www.nhi.gov.tw/Resource/webdata21717_1_20120808UniversalHealthCoverage.pdf. Accessed August 15, 2013.

13. Tseng CH. Mortality and causes of death in a national sample of diabetic patients in Taiwan. Diabetes Care. 2004;27:1605–1609.

14. Website BoNHI (updated January 2013). Http://www.nhi.gov.tw/English/webdata/webdata.aspx?menu=1&menu_id=295&WD_ID=295&webdata_id=295&webdata_id=4307. Accessed August 15, 2013.

15. Earle CC, Park ER, Lai B, et al. Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol. 2003;21:1133–1138.

16. Chang TS, Chang CM, Hsu TW, et al. The combined effect of individual and neighborhood socioeconomic status on nasopharyngeal cancer survival. PLoS One. 2013;8:e73889.

17. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619.

18. Lin CC, Lin HC. Effects of surgeon and hospital volume on 5-year survival rates following oral cancer resections: the experience of an Asian country. Surgwyre. 2008;143:343–351.

19. Stukel TA, Fisher ES, Alter DA, et al. Association of hospital spending intensity with mortality readmission rates in Ontario hospitals. JAMA. 2012;307:1037–1045.

20. Saito AM, Landrum MB, Neville BA, et al. The effect on survival of continuing chemotherapy near death. BMC Palliat Care. 2011;10:14.

21. Tang ST, Liu TW, Shyu YI, et al. Impact of age on end-of-life care for adult Taiwanese cancer decedents, 2001–2006. Palliat Med. 2012;26:80–88.

22. Warren JL, Barbera L, Bremner KE, et al. End-of-life care for lung cancer patients in the United States and Ontario. J Natl Cancer Inst. 2011;103:853–862.

23. Warnaokusuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45:309–316.

24. Sharma G, Freeman J, Zhang D, et al. Trends in end-of-life ICU use among older adults with advanced lung cancer. Chest. 2008;133:72–78.

25. Vermorken JB, Mesa R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–1127.

26. Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol. 2010;21(suppl 7):vi252–vi261.

27. Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol. 2004;22:1743–1752.

28. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23:5568–5577.

29. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2005;357:1695–1704.

30. Tribius S, Reemts E, Prosch C, et al. Global quality of life during the acute toxicity phase of multimodality treatment for patients with head and neck cancer: can we identify patients most at risk of profound quality of life decline? Oral Oncol. 2012;48:898–904.

31. Christakis NA, Lamont EB. Extent and determinants of error in doctors’ prognoses in terminally ill patients: prospective cohort study. BMJ. 2000;320:469–472.

32. Smith RC, Zimny GH. Physicians’ emotional reactions to patients. Psychosomatics. 1988;29:392–397.

33. Mack JW, Smith TJ. Reasons why physicians do not have discussions about poor prognosis, why it matters, and what can be improved. J Clin Oncol. 2012;30:2715–2717.

34. Mack JW, Cronin A, Keating NL, et al. Associations between end-of-life discussion characteristics and care received near death: a prospective cohort study. J Clin Oncol. 2012;30:4387–4395.

35. Chen ML, Chen YV, Tang ST. Latent class analysis identifies three subtypes of aggressive end-of-life care: a population-based study in Taiwan. Eur J Cancer. 2013;49:3284–3291.

36. Lee J, Turini M, Bottenman M, et al. Economic burden of head and neck cancer. Eur J Health Econ. 2004;5:70–80.

37. Lang K, Menzlin J, Earle CC, et al. The economic cost of squamous cell cancer of the head and neck: findings from linked SEER-Medicare data. Arch Otolaryngol Head Neck Surg. 2004;130:1269–1275.

38. Teno JM, Shu JE, Casaretto D, et al. Timing of referral to hospice and quality of care: length of stay and bereaved family members’ perceptions of the timing of hospice referral. J Pain Symptom Manage. 2007;34:120–125.

39. Temel JS, Greer JA, Admame S, et al. Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. J Clin Oncol. 2011;29:2319–2326.

40. Kikule E. A good death in Uganda: survey of needs for palliative care service. J Pain Symptom Manage. 2015;5:2469–2475.

41. Hardy D, Chan W, Liu CC, et al. Racial disparities in the use of hospice services according to geographic residence and socioeconomic status in an elderly cohort with nonsmall cell lung cancer. Cancer. 2011;117:1506–1515.

42. Tang ST, Wu SC, Hung YN, et al. Trends in quality of end-of-life care for Taiwanese cancer patients who died in 2000–2006. Ann Oncol. 2009;20:343–348.